EC Number   |
Inhibitors |
Structure  |
|---|
   3.4.23.38 | more |
inhibition of the enzyme blocks the essential pathway of hemoglobin degradation, leading to death of the organism |
 |
| 3.4.23.38 | more |
none of the inhibitors analyzed to date have sufficient selectivity for plasmepsin I and II, compared to their human counterparts |
|
| 3.4.23.38 | more |
plasmepsin I is a valid antimalarial drug target on two counts. First, inhibition of the enzyme correlates with inhibition of parasite growth. Second, specificity of inhibition over human aspartic proteinases is possible |
|
| 3.4.23.38 | quercetin |
- |
  |
| 3.4.23.38 | pepstatin A |
- |
|
| 3.4.23.38 | pepstatin |
IC50: about 5 nM |
|
| 3.4.23.38 | pepstatin |
- |
|
| 3.4.23.38 | Ro40-4388 |
- |
|
| 3.4.23.38 | Ro40-5576 |
- |
|
| 3.4.23.38 | (2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-N'1,N'6-bis[(4-tert-butylphenyl)carbonyl]-3,4-dihydroxyhexanedihydrazide |
- |
|
